For the quarter ending 2026-03-31, CTMX made $10,258K in revenue. -$18,257K in net income. Net profit margin of -177.98%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 10,258 | 663 | 5,963 | 18,658 |
| Research and development | 19,238 | 21,234 | 15,304 | 13,322 |
| General and administrative | 10,692 | 7,360 | 6,427 | 6,622 |
| Total operating expenses | 29,930 | 28,594 | 21,731 | 19,944 |
| Income (loss) from operations | -19,672 | -27,931 | -15,768 | -1,286 |
| Interest income | 1,490 | 1,481 | 1,592 | 1,178 |
| Other (expense) income, net | -7 | -5 | 5 | 17 |
| Income (loss) before income taxes | -18,189 | -26,455 | -14,171 | -91 |
| Provision for income taxes | 59 | 55 | 58 | 63 |
| Net income (loss) | - | -28,838* | - | - |
| Deemed dividend on warrants | - | -750* | - | - |
| Net income (loss) | - | - | -14,229 | -154 |
| Net income (loss) attributable to common stockholders | -18,248 | -29,589 | - | - |
| Unrealized loss on investments, net of tax | -9 | - | 71 | 34 |
| Total comprehensive income (loss) | -18,257 | - | -14,158 | -120 |
| Basic Average Shares | 177,273,000 | 137,935,873* | 165,004,291 | 129,075,546 |
| Diluted Average Shares | 177,273,000 | 137,935,873* | 165,004,291 | 129,075,546 |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)